Share this postSnowball ResearchAclaris Therapeutics (ACRS) appoints a new CEO who recently served as an R&D head of $6.7 billion Arena Pharma; Many analysts are upbeat about the lead drug candidate for immuno-inflammatory diseasesCopy linkFacebookEmailNotesMoreAclaris Therapeutics (ACRS) appoints a new CEO who recently served as an R&D head of $6.7 billion Arena Pharma; Many analysts are upbeat about the lead drug candidate for immuno-inflammatory diseasesApr 26, 2024∙ PaidShare this postSnowball ResearchAclaris Therapeutics (ACRS) appoints a new CEO who recently served as an R&D head of $6.7 billion Arena Pharma; Many analysts are upbeat about the lead drug candidate for immuno-inflammatory diseasesCopy linkFacebookEmailNotesMoreShareAclaris Therapeutics (ACRS)434KB ∙ PDF fileDownloadDownload This post is for paid subscribersSubscribeAlready a paid subscriber? Sign inPreviousNext
